tbuckley/cabot-search huggingface dataset:
Paris.
Authors: H. P. Newman
Journal: JAMA (1899)

<h3>To the Editor:</h3> If I were obliged to spend the rest of my days away from America—an impossible supposition—no place would seem to me so attractive and homelike as Paris. London is mighty and magnificent; Berlin, heavy and handsome; but for American lungs give me the atmosphere of a republic. It is impossible not to feel at home in this thrifty, noisy, enthusiastic home of Independence, especially for a Chicagoan. The city is not unlike our city in many ways, and the people are not unlike our people, speaking quite personally and within the circle of my own profession. I can not say too much in favor of the Frenchman as a physician. This visit to Paris, more than any previous one, has brought me into intimate contact with many of the fraternity. Although this is a time when most of the busiest men are taking their annual rest, I
Journal of Surgical Research, Philadlephia
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Th1 differentiation of circulating T lymphocytes predicts coronary endothelial dysfunction in cardiac transplant recipients J�rg Koglin, Heiko Methe, Daniela Wiegand, Bruno Meiser, Wolfgang von Scheidt. Medizinische Klinik 1, Universit�tsklinikum Grosshadern, Munich, Germany
Journal: Journal of the American College of Cardiology (2001)
Abstract 252: The Capsaicin Sensitive Afferent Neuron Innervating Skeletal Muscle is Abnormal in the Mdx Mouse
Authors: Qinglu Li, Mary Garry
Journal: Circulation Research (2017)

Duchenne muscular dystrophy (DMD) is a severe type of muscular dystrophy caused by a mutation of the dystrophin gene at locus Xp21, located on the short arm of the X chromosome. Muscle wasting and weakness are common in DMD and in the murine mdx model. We previously demonstrated Group III and IV afferent neurons, which innervate skeletal muscle and control blood pressure and heart rate in response to exercise, are abnormal in settings of ischemia and atrophy; such as cardiomyopathy. We hypothesized that these afferent neurons would also display abnormalities in the mdx mouse. To test this hypothesis, we developed a decerebrate mouse model using 10 wk and 6 mo old male BL10 WT and MDX mice to test mean arterial pressure (MAP) responses to intra-arterial capsaicin (IA-Cap; a specific stimulant of group IV afferent neurons). Mice were anesthetized and MAP was continuously recorded with a pressure transducer in the left carotid artery after which the animal was rendered decerebrate. Following decerebration, anesthesia was discontinued and IA-Cap (0,003-1ug/100ul) was delivered via the left common iliac artery. In rats, we have demonstrated this to be a valid model for evaluating MAP responses to activation of metabolically active afferent neurons. We observed that MAP increased in a dose-related fashion in both 10wk and 6 mo old WT and MDX, while 10 wk old MDX mouse had a normal response, the 6 months MDX mouse response was significantly blunted when compared to WT. To test whether these abnormalities are related to the onset of cardiomyopathy, Echocardiography was performed using 6 months old BL10 WT and MDX mice, no abnormality was found in terms of LV dimensions and function in MDX mice comparing with WT mice. Further studies will be performed to determine whether these abnormalities are inherent to changes in the skeletal muscle of the mdx mouse. We conclude that this murine model displays pressor responses to IA-Cap, similar to the rat and that MDX mice have a blunted blood pressure response to IA-Cap. These results indicate that abnormalities exist within the skeletal muscle afferent neurons in the mdx model.
Deaths.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Baseball bat-like gastric tube for end-to-side oesophageal-gastric anastomosis decreased risks of anastomotic leakage after oesophagectomy for oesophageal cancer: A retrospective propensity score matched comparative study with 613 patients
Authors: Yutian Lai, Hongjun Li, Long Tian, Xinyi Ye, Yang Hu
Journal: International Journal of Surgery (2022)
Class Reunion
Authors: Irving A. Bunkin
Journal: JAMA (1987)

September 1933. About 140 stalwarts, mostly men and a few women, arrive at the School of Medicine. They are the cream of Ivy League and New York City colleges: arrogant, self-involved, their average age about 21. Turn left or right and see Phi Beta Kappa keys dangling. (I pocket mine.) I am scared. We are in an old amphitheater listening to an introductory talk by the dean, a tall, impressive, eloquent speaker. Under his jacket the earpieces of a stethoscope are clinging to the left shoulder of his vest and the terminal diaphragm is in its lower right pocket, like a watch. June 9, 1937. Graduation. An ill-defined comfort of togetherness had been formed. One hundred twenty-four serious, subdued, but secure young folk now stalked out to diagnose and conquer disease. They separated for further training, thinking that they were at the cutting edge in medical science, without penicillin. They
Cost-effectiveness of early invasive treatment in unstable coronary artery disease: A one-year follow-up from the FRISC II invasive trial Magnus Janzon, Lars-pke Levin, Eva Swahn, FRISC II Investigators. Institution of Medicine and Care, Link�ping University, Link�ping, Sweden, CMT, Center for Medical Technology Assessment, Link�ping University, Link�ping, Sweden
Journal: Journal of the American College of Cardiology (2001)
Higher doses of intracoronary adenosine are necessary for FFR-based stent optimization William F. Fearon, Habib Samady, Eric R. Powers, Ted Feldman, Nabil Dib, E. Murat Tuzcu, Michael W. Cleman, Tony M. Chou, David J. Cohen, Atsushi Takagi, Jorge Luna, Allen Jeremias, Alan C. Yeung, Morton J. Kern, Paul G. Yock. Stanford University Medical Center, Stanford, CA
Journal: Journal of the American College of Cardiology (2001)
TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization combined with atezolizumab + bevacizumab or on-demand transarterial chemoembolization alone in patients with untreated hepatocellular carcinoma.
Authors: Masatoshi Kudo, Yabing Guo, Yongqiang Hua, Ming Zhao, Wenge Xing, Yonghong Zhang, Ruibao Liu, Zhenggang Ren, Shanzhi Gu, Zhengyu Lin, Weifu Lv, Yumeng Wang, Jiahong Dong
Journal: Journal of Clinical Oncology (2022)

TPS487 Background: In 2020, there were ̃905,000 new cases and ̃830,000 deaths from liver cancer globally, and a respective 410,038 and 391,152 in China (5-year overall survival [OS]: 14.1%). 1,2,3 Hepatocellular carcinoma (HCC) accounts for 75%–85% of liver cancers. 1 Transarterial chemoembolization (TACE) is the preferred treatment for patients with intermediate-stage unresectable HCC (uHCC); however, there are issues with the need for repeated dosing and the heterogenous target population (median OS: 13–43 mo). Treatment with TACE + systemic therapy may improve this. Although several trials reported negative results for TACE + sorafenib (sor) vs TACE alone in patients with uHCC, the TACTICS trial showed improved untreatable (unTACEable) progression-free survival (PFS) (25.2 vs 13.5 mo; P= 0.006). 4 While promising, the unmet need for combination therapies remains. The recent IMbrave150 trial showed significantly improved OS with atezolizumab (atezo) + bevacizumab (bev) vs sor (19.2 vs 13.4 mo; P= 0.0009) in patients with uHCC 5 , making it an attractive option for combination with TACE. Methods: TALENTACE (NCT047126430) is a phase III, open-label, randomized study to evaluate the efficacy and safety of TACE + atezo + bev or TACE alone in patients with uHCC. Key inclusion criteria are ≥18 years old, HCC diagnosis, no prior systemic treatment, no prior locoregional treatment of target lesions, eligible for TACE treatment, tumor max diameter + tumor number ≥6, and not a candidate for curative therapy. Patients with tumors that have macrovascular invasion (MVI) or extrahepatic spread (EHS) are excluded. Patients will be randomized (1:1) to receive TACE + atezo + bev or TACE alone. TACE will be performed by clinical demand; atezo (1200 mg) and bev (15 mg/kg) will be administered by intravenous infusion on Day 1 of each 21-day cycle. Co-primary endpoints are independent review committee-determined TACE-PFS (randomization to unTACEable progression, TACE failure/refractoriness, or death) and OS. Secondary endpoints include investigator-determined TACE-PFS; time to unTACEable progression, progression, MVI, EHS, and MVI/EHS; objective response rate, duration of response, patient reported outcomes, and incidence of adverse events. References: Sung, H., et al. CA Cancer J Clin. 2021;71(3):209–249. World Health Organisation: Globocan 2020 – China Factsheet. Available at: https://gco.iarc.fr/today/data/factsheets/populations/160-china-fact-sheets.pdf [accessed 1 June 2021] Allemani, C., et al. Lancet. 2018, 391(10125): 1023–1075. Kudo, M., et al. Gut. 2020;69(8):1492–1501. Finn, RS., et al. J Clin Oncol. 2021;39(no. 3_suppl):267–267. Clinical trial information: NCT04712643.
New and Nonofficial Remedies
Journal: JAMA (1910)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Current Medical Literature
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Restoring the oxidative balance in age-related diseases – An approach in glaucoma
Authors: Paolin Rocio Cáceres-Vélez, Flora Hui, Julie Hercus, Bang Bui, Patricia Regina Jusuf
Journal: Ageing Research Reviews (2022)

As human life expectancy increases, age-related health issues including neurodegenerative diseases continue to rise. Regardless of genetic or environmental factors, many neurodegenerative conditions share common pathological mechanisms, such as oxidative stress, a hallmark of many age-related health burdens. In this review, we describe oxidative damage and mitochondrial dysfunction in glaucoma, an age-related neurodegenerative eye disease affecting 80 million people worldwide. We consider therapeutic approaches used to counteract oxidative stress in glaucoma, including untapped treatment options such as novel plant-derived antioxidant compounds that can reduce oxidative stress and prevent neuronal loss. We summarize the current pre-clinical models and clinical work exploring the therapeutic potential of a range of candidate plant-derived antioxidant compounds. Finally, we explore advances in drug delivery systems, particular those employing nanotechnology-based carriers which hold significant promise as a carrier for antioxidants to treat age-related disease, thus reviewing the key current state of all of the aspects required towards translation.
THE DANGER OF IRRADIATED ERGOSTEROL
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
J Air Pollut Control Assoc, Pittsburgh
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Epidermolytic Hyperkeratosis
Authors: Mallory L. Foster, Jordan M. Jones, Courtney R. Schadt
Journal: JAMA Dermatology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Dose-dependent reduction in neointimal hyperplasia following coronary stenting with halofuginone, a collagen synthesis inhibitor Paul C. Keelan, LaDonna J. Camrud, Janis Donovan, Kimberly J. Yuhala, Lior Zelikovich, Debra A. Lewis, Robert S. Schwartz. Mayo Clinic and Foundation, Rochester, MN, Collgard Biopharmaceuticals, Tel Aviv, Israel
Journal: Journal of the American College of Cardiology (2001)
Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack
Authors: Yuan Fang, Weiren Liu, Zheng Tang, Xiang Ji, Yufu Zhou, Shushu Song, Mengxin Tian, Chenyang Tao, Run Huang, Guiqi Zhu, Xifei Jiang, Jun Gao, Weifeng Qu, Han Wang, Peiyun Zhou, Xiaoling Wu, Lei Jin, Haixiang Sun, Zhenbin Ding, Yuanfei Peng, Shimin Zhao, Jian Zhou, Jia Fan, Wei Xu, Yinghong Shi
Journal: Hepatology (2022)

Background and Aims: Monocarboxylate transporter (MCT) 4 is a high‐affinity lactate transporter that is primarily involved in the maintenance of intracellular pH homeostasis and highly expressed in different tumors. However, the role of MCT4 in modulating immune responses against HCC remains unknown. Approach and Results: In this study, we demonstrated that MCT4 was overexpressed in HCC, which was associated with poor prognosis in patients. Genetic or pharmacological inhibition of MCT4 using VB124 (a highly potent MCT4 inhibitor) suppressed HCC tumor growth in immunocompetent mice model by enhancing CD8 + T cell infiltration and cytotoxicity. Such improved immunotherapy response by MCT4 targeting was due to combined consequences characterized by the alleviated acidification of tumor microenvironment and elevated the chemokine (C‐X‐C motif) ligand (CXCL) 9/CXCL10 secretion induced by reactive oxygen species/NF‐κB signaling pathway. Combining MCT4 inhibition improved the therapeutic benefit of anti–programmed cell death 1 immunotherapy in HCC and prolonged mice survival. Moreover, higher MCT4 expression was observed in tumor tissues from nonresponder patients with HCC receiving neoadjuvant therapy with toripalimab. Conclusions: Our results revealed that lactate exportation by MCT4 has a tumor‐intrinsic function in generating an immunosuppressive HCC environment and demonstrated the proof of the concept of targeting MCT4 in tailoring HCC immunotherapeutic approaches.
US Insurer Spending on Ivermectin Prescriptions for COVID-19
Authors: Kao-Ping Chua, Rena M. Conti, Nora V. Becker
Journal: JAMA (2022)

Eduardo López-Medina, MD, MSc; Pío López, MD; Isabel C. Hurtado, MD; Diana M Dávalos, MD, MPH, DrPH; Oscar Ramirez, MD, MPhil; Ernesto Martínez, MD; Jesus A. Díazgranados, MD; José M. Oñate, MD; Hector Chavarriaga, MD, MS; Sócrates Herrera, MD; Beatriz Parra, PhD; Gerardo Libreros, PhD; Roberto Jaramillo, MD; Ana C. Avendaño, MD; Dilian F. Toro, MD; Miyerlandi Torres, DrPH; Maria C. Lesmes, MD; Carlos A. Rios, MD; Isabella Caicedo, MD
Clinical, angiographic, and intravascular ultrasound predictors of target lesion revascularization and late cardiac events after stent implantation in saphenous sein grafts Javed M. Ahmed, George D. Dangas, Roxana Mehran, Augusto D. Pichard, Lowell F. Satler, Kenneth M. Kent, Mun K. Hong, Gregg W. Stone, Martin B. Leon. Washington Hospital Center, Washington, DC, Cardiovascular Research Foundation, New York, NY
Journal: Journal of the American College of Cardiology (2001)
News &amp; Notes
Journal: Journal of Allergy and Clinical Immunology (2020)

Cutting-edge research has revolutionized our understanding of immune mechanisms and led to the development of novel therapies for the management of congenital disorders of immunity, expanded our appreciation of phenotype-genotype variability, and identified overlaps between allergic and immunologic disorders.This session will highlight current and emerging paradigms in congenital disorders of immunity and assist the learner in expanding their scope of practice related to immune based disorders. Novel Experimental Therapies for Allergic DiseasesThis session will highlight recent and highly innovative experimental therapies for allergic diseases.These therapies have interesting mechanisms of action, show efficacy in animal models of allergic diseases and are promising candidates for future clinical use.Highlighted therapies include an anti-galectin-10 antibody that dissolves Charcot-Leyden crystals in airways and thereby reduces experimental asthma, an anti-IL1R3 antibody that targets the common co-receptor for six members of the IL1 family and thereby blocks multiple inflammatory pathways in experimental asthma, and microbiota therapy that induces RORgt-positive regulatory T cells and thereby suppresses food allergy.